摘要
目的探讨重组人白介素-11治疗急性白血病化疗后血小板减少症的疗效和安全性分析。方法选取从2015年1月~2016年12月患有急性白血病化疗后血小板较少症患者60例,随机分为常规组与观察组,各30例。常规组采取常规的治疗方法,观察组患者给予重组人白介素-11治疗,对比两组治疗效果。结果通过对两组患者予以不同的治疗方法,观察组治疗有效率明显优于常规组,观察组即为89.9%,常规组为76.6%,两组比较差异明显具有统计学意义(P<0.05);同时,对两组患者血小板各项指标进行了比较,其中包括血小板最低值、恢复时间和人均血小板输注量,结果显示察组明显优于常规组患者,差异明显具有统计学意义(P<0.05)。结论对患者实施重组人白介素-11药物介入治疗,可有效的提高患者治疗效果,缩短了患者住院时间,加快了血小板的恢复,有利于患者康复。
Objective To investigate the efficacy and safety of recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy in acute leukemia. Methods 60 patients with thrombocytopenia after acute leukemia chemotherapy from January 2015 to December 2016 were randomly divided into routine group and observation group and 30 cases/group. The conventional group took conventional treatment. The observation group patients were treated with recombinant human interleukin-11 and the treatment effects of the two groups were compared. Results Through different treatment methods for the two groups of patients, the observation group was significantly more effective than the conventional group. The observation group was 89.9%, and the conventional group was 76.6%. The difference between the two groups was statistically significant（P〈0.05）.At the same time, the platelet indexes of the two groups of patients were compared, including platelet minimum value, recovery time, and platelet transfusion per capita. The results showed that the observation group was significantly better than the conventional group, and the difference was statistically significant（P〈0.05）. Conclusion The implementation of recombinant human interleukin-11 drug interventional therapy in patients can effectively improve the treatment effect of patients, shorten the hospitalization time of patients, accelerate the recovery of platelets, and help patients recover.
作者
代恩艳
Dai Enyan(Department of Hematology,Yinan County People＇s Hospital,Yinan,Shandong,276300,China)
出处
《当代医学》
2018年第20期74-76,共3页
Contemporary Medicine
